XTX Topco Ltd Decreases Stock Holdings in Guardant Health, Inc. (NASDAQ:GH)

XTX Topco Ltd lowered its holdings in Guardant Health, Inc. (NASDAQ:GH) by 49.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,833 shares of the company’s stock after selling 17,325 shares during the period. XTX Topco Ltd’s holdings in Guardant Health were worth $409,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. increased its position in Guardant Health by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock worth $102,000 after buying an additional 796 shares during the last quarter. JNBA Financial Advisors bought a new position in shares of Guardant Health during the 3rd quarter worth $26,000. Wexford Capital LP increased its holdings in Guardant Health by 13.0% in the 3rd quarter. Wexford Capital LP now owns 10,081 shares of the company’s stock worth $231,000 after acquiring an additional 1,158 shares during the last quarter. Ashton Thomas Securities LLC bought a new stake in Guardant Health in the 3rd quarter valued at about $34,000. Finally, Quarry LP purchased a new stake in Guardant Health during the second quarter valued at about $44,000. Institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Performance

Shares of GH opened at $34.76 on Monday. The company has a current ratio of 6.22, a quick ratio of 5.85 and a debt-to-equity ratio of 16.70. The stock has a 50-day moving average price of $27.92 and a 200-day moving average price of $28.16. The company has a market cap of $4.29 billion, a PE ratio of -8.20 and a beta of 1.26. Guardant Health, Inc. has a 12-month low of $15.81 and a 12-month high of $38.53.

Guardant Health (NASDAQ:GH) last announced its earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.33). The company had revenue of $191.48 million for the quarter, compared to the consensus estimate of $170.49 million. Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The company’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.73) earnings per share. As a group, equities analysts forecast that Guardant Health, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Meghan V. Joyce sold 2,896 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the sale, the director now directly owns 7,648 shares in the company, valued at approximately $228,675.20. The trade was a 27.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 5.50% of the stock is owned by company insiders.

Analyst Ratings Changes

GH has been the topic of several research reports. The Goldman Sachs Group boosted their price target on shares of Guardant Health from $32.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. boosted their target price on shares of Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. UBS Group raised their price target on Guardant Health from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, August 21st. Sanford C. Bernstein reduced their price target on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, October 30th. Finally, Leerink Partners dropped their price objective on Guardant Health from $60.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Fifteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $40.60.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.